Skip to content
Ceftobiprole
Ceftobiprole is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DI: Other cephalosporins and penems in atc
— J01DI01: Ceftobiprole medocaril
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Staphylococcal skin infectionsD013207EFO_1001849L004—2——6
PneumoniaD011014EFO_0003106J18——3—14
BacteremiaD016470EFO_0003033R78.81—11——2
Infectious skin diseasesD012874——2——2
Bacterial skin diseasesD017192——2——2
Healthcare-associated pneumoniaD000077299——1——1
NeutropeniaD009503D70——1——1
FeverD005334HP_0001945R50.9——1——1
Pseudomonas infectionsD011552EFO_0001076——1——1
Gram-positive bacterial infectionsD016908——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MeningitisD008581EFO_0000584G03—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Streptococcal infectionsD013290EFO_10014764————4
Bacterial infectionsD001424A491————1
ObesityD009765EFO_0001073E66.91————1
AcremoniumD0001641————1
Drug resistanceD004351Z16.301————1
Ventilator-associated pneumoniaD053717EFO_1001865J95.8511————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral hemorrhageD002543————11
Subarachnoid hemorrhageD013345EFO_0000713I60————11
Drug monitoringD016903————11
Renal insufficiencyD051437HP_0000083N19————11
Hepatic insufficiencyD048550————11
Immunosuppression therapyD007165————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFTOBIPROLE
INNceftobiprole
Description
Ceftobiprole is a fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP). It has a role as an antimicrobial agent. It is a cephalosporin and a member of thiadiazoles.
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1
Identifiers
PDB—
CAS-ID209467-52-7
RxCUI—
ChEMBL IDCHEMBL520642
ChEBI ID—
PubChem CID135413542
DrugBankDB04918
UNII ID5T97333YZK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,132 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details